Bulletin du cancer最新文献

{"title":"[Comparison of gemcitabine production costs in individualized and standardized doses].","authors":"Mélanie Closset, Louise Lombet, Justine Hubert, Laura Soumoy, Jean-Daniel Hecq, Pascal Odou, Laurence Galanti","doi":"10.1016/j.bulcan.2025.02.008","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.02.008","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer chemotherapy doses are often adapted to patients' body surface area and produced individually. Alternatively, dose-banding promotes batch production of clinically defined fixed doses, for which a standard deviation of±5% determines a band incorporating individual doses calculated on the basis of body surface area. The aim is to compare the costs of individualized and batch production of gemcitabine in a centralized chemotherapy reconstitution unit.</p><p><strong>Method: </strong>The study was carried out using a cost-minimization analysis. The first step was to identify the percentage of gemcitabine preparations eligible for standardization over a one-year period, and to define the standardized doses of clinical interest, taking into account a standard deviation of±5%. The second step was to compare the direct and indirect costs of individualized production with those of mass production.</p><p><strong>Results: </strong>The percentage of standardizable preparations was evaluated at 69.8%, with standardized doses of 1500mg±5%, 1600mg±5%, 1800mg±5%, 2000mg±5% and 2200mg±5%. Comparison of production costs for a total of 324 bags over one year showed that dose-banding reduced costs by 7%.</p><p><strong>Discussion: </strong>The cost difference between individualized production and batch production of standardized doses of gemcitabine bags is in favor of dose-banding. The analysis could be extended to other anticancer molecules.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143766113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress on the role and molecular mechanism of PRDX4 in malignant tumors.","authors":"Li Xuelian, Shang Panfeng, Zhang Xingxing, Ma Lilong","doi":"10.1016/j.bulcan.2025.02.009","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.02.009","url":null,"abstract":"<p><p>Peroxiredoxin IV (PRDX4) is an important member of the Peroxiredoxin (PRDX) family. Studies in recent years have shown that PRDX4, as an antioxidant enzyme, plays a crucial role in processes such as protein folding, DNA damage, inflammatory responses, and tumorigenesis. At the molecular mechanism level, PRDX4 can act as a key regulatory factor in redox signaling pathways and regulate the levels of reactive oxygen species (ROS) within cells through oxidative defense mechanisms. Although there is evidence supporting that PRDX4 may become a new target for the treatment of certain malignant tumors, its biological functions and related molecular mechanisms in different types of malignant tumors are still controversial and not fully elucidated, thus requiring further in - depth exploration. This review aims to summarize the roles of PRDX4 in malignant tumors and its potential molecular mechanisms in recent years, with a view to providing new perspectives for future research.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[First line pembrolizumab plus chemotherapy in unresectable pleural mesothelioma].","authors":"Sofiene Fendri, Elisa Gobbini","doi":"10.1016/j.bulcan.2025.02.015","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.02.015","url":null,"abstract":"","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Update on marginal zone lymphoma classification, diagnosis and treatment in 2024].","authors":"Lucie Oberic, Krimo Bouabdallah, Sylvain Carras, Catherine Thieblemont","doi":"10.1016/j.bulcan.2025.01.013","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.01.013","url":null,"abstract":"<p><p>Marginal zone lymphoma (MZL) is the third most frequent lymphoma in Western countries with an increasing incidence with age. There are different histologic subtypes: Splenic MZL (SMZL), Nodal MZL (NZML), Extranodal MZL (EMZL) or MALT lymphoma and more recently, a novel entity called splenic diffuse red pulp small B-cell lymphoma. The accurate diagnosis relies on morphologic, phenotypic, cytogenetic and molecular features in order to rule out other indolent non-Hodgkin lymphomas. First line treatment depends on MZL subtypes: depending on localized or disseminated disease, MALT lymphoma are managed with radiotherapy on immunochemotherapy. SMZL, when requiring therapy, are treated with splenectomy ore more frequently monotherapy Rituximab or immunochemotherapy depending on age, comorbidities and tumor burden. Management of NMZL is often similar to Follicular lymphoma treatment. Treatment of refractory or relapsed MZL takes into account the time between the diagnosis and the progression, the nature and outcomes of previous therapies and the general condition of the patient. Conventional treatments may be a suitable option but novel therapies are more frequently used. In this review, we focus on the role of Bruton Tyrosine Kinases (where only Zanubrutinib has marketing authorization in France), PI3Kinases, Syk and BCL-2 inhibitors as well as on the results of immunomodulatory drugs and more recently the use of bispecific antibodies and T-cell chimeric antigen receptor (CAR-T cell).</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Osimertinib with or without chemotherapy - non-small cell lung cancer with EGFR mutations (exon 19 deletion or L858R of exon 21)].","authors":"Noémie Drappier, Merouane Messekher","doi":"10.1016/j.bulcan.2025.02.005","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.02.005","url":null,"abstract":"","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Navigating the storm: scientific disputes, misinformation, ethical questioning].","authors":"Jacques-Olivier Bay, Stéphane Vignot, Nathalie Mazure, Philippe Pourquier","doi":"10.1016/j.bulcan.2025.03.004","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.03.004","url":null,"abstract":"","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Assessment of the relevance of diagnostic tools for undernutrition in patients with head and neck cancers].","authors":"Guillaume Buiret, Ghislain Riffard, Laurence Chenevier, Lisa Meniscus, Claire Combe","doi":"10.1016/j.bulcan.2025.02.016","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.02.016","url":null,"abstract":"<p><strong>Introduction: </strong>Malnutrition is a major prognostic factor in head and neck cancers. The French National Authority for Health recommends several methods for diagnosing malnutrition. The main aim of this study was to determine whether the methods used to diagnose malnutrition prior to any treatment by the dietician, the adapted physical activity teacher and impedancemetry were complementary or redundant.</p><p><strong>Method: </strong>Sixty-six patients aged 18 to 70 with head and neck cancer who had undergone nutritional assessment using the three methods prior to cancer treatment were retrospectively included. The mean age was 54.9 years. The most frequent location was oropharyngeal cancer.</p><p><strong>Results: </strong>Thirty-four patients were malnourished at the time of diagnosis of their head and neck cancer according to at least one of the tests (52.3%). The specificities of the different tests used ranged from 3.3 to 55.2%, and those of each method (diet, adapted physical activity and impedancemetry) from 48.4 to 64.7%. The diagnosis of malnutrition by two of the three methods was concordant in 26.1% to 38.5% of cases, and by all three methods in 2.9% of cases of malnutrition (the diagnosis of malnutrition was made by all three methods in a single patient).</p><p><strong>Conclusion: </strong>The combined use of assessment by a dietician, an adapted physical activity teacher and impedancemetry offers a more complete, complementary and non-redundant approach to the diagnosis of malnutrition in patients with head and neck cancer, which can probably be generalised to all patients with solid or haematological cancer.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Toripalimab in combination with cisplatin and gemcitabine in recurrent or metastatic nasopharyngeal carcinomas (UCNT RM) in first-line treatment].","authors":"Thomas Cochin, Esma Saâda-Bouzid","doi":"10.1016/j.bulcan.2025.02.006","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.02.006","url":null,"abstract":"","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Atezolizumab in first line in patients with metastatic non-small lung cancer who are platinum-doublet ineligible].","authors":"Faustine Enoch, Elvire Pons-Tostivint","doi":"10.1016/j.bulcan.2025.02.007","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.02.007","url":null,"abstract":"","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chondrosarcomas: Multidisciplinary review and practical recommendations, on behalf of GroupOs.","authors":"Pascaline Boudou-Rouquette, Nadège Corradini, Marie-Pierre Sunyach, Frédérique Larousserie, Camille Cordero, Aude Marie Cardine, Sophie Piperno-Neumann, Emmanuelle Bompas, Gonzague de Pinieux, François Gouin, Nayla Nicolas, Amandine Crombé, Sylvie Helfre, Antoine Feydy, Marie Faruch, David Biau","doi":"10.1016/j.bulcan.2024.07.013","DOIUrl":"https://doi.org/10.1016/j.bulcan.2024.07.013","url":null,"abstract":"<p><p>Chondrosarcomas are rare tumors occurring in middle age and older adults, defined by malignant cartilaginous matrix-producing neoplasms. Chondrosarcomas represent a heterogeneous group of tumors with diverse characteristics, management strategies and prognosis. The aim is to establish recommendations to support optimal practice for the diagnosis and treatment of chondrosarcomas within the framework of an expert group at the request of GroupOs and the French Sarcoma Group. The recommendations were developed by a multidisciplinary working and underwent thorough proofreading. The level of evidence in scientific literature and the grading of recommendations by the French Haute Autorité de santé (HAS) were taken into account. Key recommendations cover: (i) diagnosis, management and follow-up enchondromatosis; (ii) initial assessment, diagnosis and staging of cartilaginous tumor; (iii) management of low-grade, clear cell and high-grade, localized resectable chondrosarcomas; (iv) indications for radiotherapy in chondrosarcomas; (v) management of locally advanced and metastatic disease; (vi) management of mesenchymal chondrosarcomas. Surgical resection at a specialized center remains the mainstay for localized chondrosarcomas management, tailored to grade and anatomical location. Limited evidence supports the use of neoadjuvant or adjuvant treatment in chondrosarcomas, except in mesenchymal chondrosarcomas. For patients with dedifferentiated chondrosarcomas, neo or adjuvant treatment with osteosarcoma-like regimens may be proposed. In cases of recurrence or metastasis, local treatment should be prioritized or participation in clinical trials including new targeted or immune therapies should be considered. This article presents consensus recommandations from adult and pediatric sarcoma experts of various disciplines on the practical management of chondrosarcomas patients.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}